Prognostic value of high-risk cytogenetic abnormalities inmultiple myeloma
- VernacularTitle:高危细胞遗传学异常在多发性骨髓瘤中的预后价值
- Author:
Xuxing SHEN
1
;
Jiapei YU
1
;
Rui GUO
1
;
Ying XU
1
;
Yuanyuan JIN
1
;
Qinglin SHI
1
;
Lijuan CHEN
1
Author Information
- Publication Type:Journal Article
- From: Chinese Journal of Hematology 2025;46(10):958-962
- CountryChina
- Language:Chinese
- Abstract: To retrospectively analyze the clinical data of 465 newly diagnosed patients with multiple myeloma (NDMM) admitted to the First Affiliated Hospital of Nanjing Medical University from December 2016 to December 2024, and compare the prognostic value of high-risk cytogenetic abnormalities (HRCAs) in NDMM patients under mSMART 3.0 and mSMART 4.0 risk stratification systems. The results showed that in both stratification systems, the prognosis of high-risk patients was worse than that of standard-risk patients. Moreover, a higher number of HRCAs was associated with a worse prognosis. The mSMART 4.0 system, which considers the coexistence of various cytogenetic abnormalities, provides a more precise definition of HRCA than mSMART 3.0. It demonstrates a superior ability to differentiate between different categories of cytogenetic risk.
